A detailed history of M&R Capital Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, M&R Capital Management Inc holds 6,170 shares of BMY stock, worth $353,726. This represents 0.07% of its overall portfolio holdings.

Number of Shares
6,170
Previous 5,546 11.25%
Holding current value
$353,726
Previous $230,000 38.7%
% of portfolio
0.07%
Previous 0.06%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 02, 2024

BUY
$39.66 - $51.75 $24,747 - $32,292
624 Added 11.25%
6,170 $319,000
Q2 2024

Jul 02, 2024

SELL
$40.25 - $52.99 $3,582 - $4,716
-89 Reduced 1.58%
5,546 $230,000
Q1 2024

Apr 02, 2024

SELL
$47.98 - $54.4 $25,765 - $29,212
-537 Reduced 8.7%
5,635 $305,000
Q4 2023

Jan 02, 2024

SELL
$48.48 - $57.85 $123,236 - $147,054
-2,542 Reduced 29.17%
6,172 $316,000
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $142,814 - $159,688
-2,467 Reduced 22.06%
8,714 $505,000
Q2 2023

Jul 05, 2023

SELL
$63.71 - $70.74 $117,544 - $130,515
-1,845 Reduced 14.16%
11,181 $715,000
Q1 2023

Apr 03, 2023

SELL
$65.71 - $74.53 $43,565 - $49,413
-663 Reduced 4.84%
13,026 $902,000
Q4 2022

Jan 11, 2023

BUY
$68.48 - $81.09 $295,080 - $349,416
4,309 Added 45.94%
13,689 $0
Q3 2022

Oct 03, 2022

BUY
$0.13 - $76.84 $227 - $134,470
1,750 Added 22.94%
9,380 $666,000
Q2 2022

Jul 05, 2022

BUY
$72.62 - $79.98 $17,065 - $18,795
235 Added 3.18%
7,630 $587,000
Q1 2022

Apr 04, 2022

BUY
$61.48 - $73.72 $116,504 - $139,699
1,895 Added 34.45%
7,395 $540,000
Q4 2021

Jan 07, 2022

SELL
$53.63 - $62.52 $37,541 - $43,764
-700 Reduced 11.29%
5,500 $342,000
Q3 2021

Oct 05, 2021

BUY
$59.17 - $69.31 $11,834 - $13,862
200 Added 3.33%
6,200 $366,000
Q1 2021

Apr 01, 2021

SELL
$59.34 - $66.74 $67,647 - $76,083
-1,140 Reduced 15.97%
6,000 $378,000
Q4 2020

Jan 05, 2021

SELL
$57.74 - $65.43 $34,182 - $38,734
-592 Reduced 7.66%
7,140 $442,000
Q3 2020

Oct 01, 2020

BUY
$57.43 - $63.64 $22,972 - $25,456
400 Added 5.46%
7,732 $466,000
Q2 2020

Jul 01, 2020

SELL
$54.82 - $64.09 $714,414 - $835,220
-13,032 Reduced 64.0%
7,332 $430,000
Q1 2020

Apr 02, 2020

SELL
$46.4 - $67.43 $63,939 - $92,918
-1,378 Reduced 6.34%
20,364 $1.14 Million
Q4 2019

Jan 07, 2020

BUY
$49.21 - $64.19 $7,381 - $9,628
150 Added 0.69%
21,742 $1.39 Million
Q3 2019

Oct 02, 2019

SELL
$42.77 - $50.71 $12,831 - $15,213
-300 Reduced 1.37%
21,592 $1.09 Million
Q1 2019

Apr 29, 2019

SELL
$45.12 - $53.8 $92,586 - $110,397
-2,052 Reduced 8.57%
21,892 $1 Million
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $287,684 - $373,057
-5,900 Reduced 19.77%
23,944 $1.24 Million
Q3 2018

Nov 09, 2018

SELL
$55.19 - $62.25 $16,557 - $18,675
-300 Reduced 1.0%
29,844 $1.85 Million
Q2 2018

Aug 08, 2018

SELL
$50.53 - $62.98 $56,138 - $69,970
-1,111 Reduced 3.55%
30,144 $1.67 Million
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $113,967 - $131,199
1,902 Added 6.48%
31,255 $1.98 Million
Q4 2017

Feb 14, 2018

SELL
$59.94 - $65.35 $39,979 - $43,588
-667 Reduced 2.22%
29,353 $1.8 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $27,615 - $31,870
-500 Reduced 1.64%
30,020 $1.91 Million
Q2 2017

Aug 15, 2017

BUY
N/A
30,520
30,520 $1.73 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track M&R Capital Management Inc Portfolio

Follow M&R Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&R Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on M&R Capital Management Inc with notifications on news.